Saturday 17 October 2026
Export RGEN’s income statement to Excel — free account
Repligen Corporation
RGEN Healthcare Medical Instruments & Supplies
Repligen Corporation’s revenue for fiscal 2025 (year ended December 2025) was $738.3 million, up 16.4% from fiscal 2024. In the quarter to June 2026, revenue grew 11.9%, EPS fell 65.4%, free cash flow grew 27.1% and total debt rose 3.25%, each against the same quarter a year earlier.
175.20
8.97
−4.87%
Follow RGEN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
181.92 | 128.07 | 188.34 | 4,455.67 |
+8 more quarters Free account |
P/S ratio |
9.80 | 8.70 | 12.48 | 10.62 | |
P/FCF ratio |
126.01 | 119.86 | 215.98 | 134.37 | |
P/Operating CF |
234.93 | 234.66 | 358.49 | 156.36 | |
P/B ratio |
3.64 | 3.15 | 4.38 | 3.61 | |
Price to Tangible BV |
11.84 | 10.53 | 15.22 | 13.08 | |
EV/Sales |
9.56 | 8.48 | 12.27 | 10.42 | |
EV/EBITDA |
46.62 | 40.12 | 60.17 | 78.27 | |
EV/Operating CF |
55.67 | 49.51 | 77.15 | 56.38 | |
EV/FCF |
122.90 | 116.82 | 212.32 | 131.85 | |
Quick Ratio |
7.30 | 7.42 | 6.82 | 6.85 | |
Current Ratio |
9.05 | 9.20 | 8.37 | 8.36 | |
Net Debt/EBITDA |
(5.52) | (5.94) | (5.35) | (6.62) | |
Debt/Assets |
18.68% | 18.65% | 18.38% | 18.40% | |
Debt/Equity |
0.26 | 0.26 | 0.26 | 0.26 | |
Asset Turnover |
0.27 | 0.26 | 0.26 | 0.25 | |
Operating CF/Net income |
6.54 | 3.40 | 1.93 | 3.23 | |
Capex/Depreciation |
(0.18) | (0.20) | (0.33) | (0.36) | |
Interest Coverage |
2.47 | 2.86 | 3.25 | 3.11 | |
Research and Development Expense of Revenue |
7.06% | 7.44% | 7.03% | 7.51% | |
Selling, General and Administrative Expense of Revenue |
37.53% | 39.40% | 38.01% | 39.02% | |
Intangible Assets out of Total Assets |
0.50 | 0.50 | 0.51 | 0.52 | |
Share Based Compensation of Revenue |
3.93% | 4.28% | 4.03% | 4.75% | |
Graham Net Nets |
0.05 | 0.05 | 0.03 | 0.03 | |
Graham Number |
25.13 | 27.81 | 27.08 | 5.00 | |
Earnings Yield |
0.55% | 0.78% | 0.53% | 0.02% | |
Free Cash Flow Yield |
0.79% | 0.83% | 0.46% | 0.74% | |
Revenue per Share |
3.62 | 3.45 | 3.52 | 3.36 | |
Operating CF per Share |
0.58 | 0.50 | 0.46 | 0.85 | |
Capex per Share |
(0.11) | (0.09) | (0.14) | (0.10) | |
Free Cash Flow per Share |
0.47 | 0.41 | 0.31 | 0.76 | |
Cash per Share |
14.37 | 13.92 | 13.65 | 13.31 | |
Shareholders Equity per Share |
37.44 | 37.36 | 37.45 | 37.02 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
37.44 | 37.36 | 37.45 | 37.02 | |
Free Cash Flow |
26.70 | 23.35 | 17.59 | 42.71 | |
Working Capital |
1,067.90 | 1,035.15 | 1,001.56 | 965.35 | |
Capital Expenditures |
(6.07) | (4.95) | (8.11) | (5.39) | |
Net Current Asset Value |
362.41 | 336.05 | 293.82 | 255.86 | |
EV/EBIT |
116.20 | 100.28 | 164.20 | 9,247.62 | |
Capex to Sales |
0.03 | 0.03 | 0.04 | 0.03 | |
Price to Operating Income |
119.14 | 102.89 | 167.03 | 9,424.74 | |
| Other line items | |||||
Average Receivables |
157.33 | 149.48 | 146.35 | 139.00 | |
Average Payables |
29.43 | 30.80 | 31.07 | 25.39 | |
Average Inventory |
171.23 | 166.18 | 156.71 | 171.39 | |
Average Assets |
2,925.90 | 2,891.46 | 2,889.68 | 2,877.18 | |
Average Common Equity |
2,086.89 | 2,045.47 | 2,039.42 | 2,049.89 |
Columns are period end dates